We have been preparing libraries for Illumina GA and we have some problems with RNA-seq libraries. The issue that we are having is that we are seeing two peaks in bioanalyzer data (attached ppt). We are seeing this in all our RNA seq samples - no matter what organism used. We are using Illumina RNAseq kit. have anyone seen something like this? I would really appreciate any advice.
-
-
I've seen this with ChIP-Seq libraries. I think the double peak is due to library PCR dimers forming. This is similar to primer-dimers but forms from PCR products dimerizing.
You see this more often if you use high cycle numbers in your amplification. -
This happens in about a third of my RNA-Seq library preps. Try using the ultrapure T4 ligase from Enzymatics and titrating the amount of primers in the final step, going down by 0.1ul amounts from 1ul.Comment
-
two rounds DSN normalization
hello
has anyone tried to do two rounds of DSN normalization (specifically for RNA-seq)? If so, how did you do it and how did it go? Thanks.Comment
-
I have done just one round of DSN normalization using Illumina's DSN normalization kit. The protocol of which can be found at http://qb3.berkeley.edu/gsl/Protocol...OT_RELEASE.pdfOriginally posted by zorph View PostComment
-
We are also seeing double peaks in our RNA-seq library preps, even though all samples have been gel extracted at 350bp. Does anyone know how it is possible to still have 700 bp fragments after gel extraction and what we can do to remove the longer fragments? Thanks.Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM
Comment